PLSE - Pulse Biosciences, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Hayward,
United States
Type: Equity
PLSE price evolution
PLSE
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.2 | $34.88 | $44.37 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $80.41 | $27.24 | $35.85 | $45.33 |
| Long term investments | ||||
| Property, plant & equipment | $7.81 | $8.13 | $8.44 | $8.78 |
| Goodwill & intangible assets | $4.34 | $4.51 | $4.68 | |
| Total noncurrent assets | $13.19 | $13.31 | $13.83 | |
| Total investments | ||||
| Total assets | $93.05 | $40.43 | $49.16 | $59.15 |
| Current liabilities | ||||
| Accounts payable | $1.73 | $1.64 | $1.71 | $1.84 |
| Deferred revenue | ||||
| Short long term debt | $1.15 | $1.1 | $1.06 | |
| Total current liabilities | $6.74 | $5.96 | $5.08 | $6.71 |
| Long term debt | $7.5 | $7.8 | $8.09 | |
| Total noncurrent liabilities | $7.5 | $7.8 | $8.09 | |
| Total debt | $8.64 | $8.9 | $9.14 | |
| Total liabilities | $13.91 | $13.46 | $12.88 | $14.79 |
| Shareholders' equity | ||||
| Retained earnings | -$371.12 | -$358.44 | -$347.05 | -$336.92 |
| Other shareholder equity | ||||
| Total shareholder equity | $26.97 | $36.29 | $44.36 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.37 | $61.14 | $28.61 | $12.46 |
| Short term investments | $8.01 | |||
| Net receivables | $0.06 | |||
| Inventory | $5.82 | |||
| Total current assets | $45.33 | $62.15 | $36.63 | $22.34 |
| Long term investments | ||||
| Property, plant & equipment | $8.78 | $10.02 | $11.25 | $11.92 |
| Goodwill & intangible assets | $4.68 | $5.34 | $6.01 | $6.67 |
| Total noncurrent assets | $13.83 | $15.73 | $17.62 | $18.95 |
| Total investments | $8.01 | |||
| Total assets | $59.15 | $77.88 | $54.25 | $41.29 |
| Current liabilities | ||||
| Accounts payable | $1.84 | $1.57 | $2.9 | $1.72 |
| Deferred revenue | $0.02 | |||
| Short long term debt | $1.06 | $1.81 | $1.21 | $0.54 |
| Total current liabilities | $6.71 | $5.98 | $8.52 | $7.58 |
| Long term debt | $8.09 | $65 | $10.04 | $10.81 |
| Total noncurrent liabilities | $8.09 | $74.14 | $10.04 | $10.81 |
| Total debt | $9.14 | $75.96 | $11.25 | $11.36 |
| Total liabilities | $14.79 | $80.13 | $18.56 | $18.4 |
| Shareholders' equity | ||||
| Retained earnings | -$336.92 | -$294.7 | -$236.2 | -$172.54 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | $44.36 | -$2.25 | $35.69 | $22.89 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.23 | $6.74 | $7.8 | |
| Selling, general & administrative | $4.5 | $3.87 | $4.73 | |
| Total operating expenses | $11.73 | $10.62 | $12.53 | |
| Operating income | -$11.73 | -$10.62 | -$12.53 | |
| Income from continuing operations | ||||
| EBIT | -$11.38 | -$9.66 | -$14.06 | |
| Income tax expense | ||||
| Interest expense | $0.48 | -$2.13 | ||
| Net income | ||||
| Net income | -$11.38 | -$10.14 | -$11.93 | |
| Income (for common shares) | -$11.38 | -$10.14 | -$11.93 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.7 | $1.42 | ||
| Cost of revenue | $11.94 | $1.97 | ||
| Gross Profit | -$11.24 | -$0.55 | ||
| Operating activities | ||||
| Research & development | $27.8 | $20.84 | $28.64 | $26.44 |
| Selling, general & administrative | $15.78 | $25.97 | $33.82 | $22.86 |
| Total operating expenses | $43.57 | $46.81 | $62.46 | $49.97 |
| Operating income | -$43.57 | -$58.06 | -$63.01 | -$49.97 |
| Income from continuing operations | ||||
| EBIT | -$43.57 | -$58.06 | -$64.31 | -$49.85 |
| Income tax expense | ||||
| Interest expense | -$1.36 | $0.45 | -$0.65 | |
| Net income | ||||
| Net income | -$42.21 | -$58.51 | -$63.66 | -$49.85 |
| Income (for common shares) | -$42.21 | -$58.51 | -$63.66 | -$49.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$11.38 | -$10.14 | -$11.93 | |
| Operating activities | ||||
| Depreciation | $0.3 | $0.3 | $0.3 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.05 | $1.76 | $3.34 | |
| Total cash flows from operations | -$8.39 | -$9.78 | -$6.78 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.01 | -$0.04 | |
| Investments | ||||
| Total cash flows from investing | -$0.07 | -$0.03 | -$0.01 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.3 | $0.8 | |
| Net borrowings | ||||
| Total cash flows from financing | $61.94 | -$0.27 | $0.3 | $0.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $34.67 | -$8.69 | -$9.48 | -$6.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$42.21 | -$58.51 | -$63.66 | -$49.85 |
| Operating activities | ||||
| Depreciation | $1.21 | $1.35 | $1.15 | $1.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.18 | $5.19 | $14.6 | $10.07 |
| Total cash flows from operations | -$33.04 | -$47.01 | -$54.1 | -$35.37 |
| Investing activities | ||||
| Capital expenditures | -$0.12 | -$0.4 | -$0.44 | -$0.44 |
| Investments | $8 | $10.48 | ||
| Total cash flows from investing | -$0.12 | -$0.4 | $7.56 | $10.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.39 | $15.38 | $62.51 | $30.89 |
| Net borrowings | -$0.01 | $64.56 | $0.41 | |
| Total cash flows from financing | $16.39 | $79.94 | $62.69 | $30.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$16.77 | $32.52 | $16.15 | $5.56 |
News
Fundamentals
| Market cap | $1.11B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 61.52M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 11.93 |
| Quick ratio | N/A |